Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Observational Study for Ex-vivo Evaluation of the Likelihood of Response to an Experimental Tolerance Restoration Therapy in Subjects Diagnosed With Multiple Sclerosis (MS)

NCT05663853 is registered in ClinicalTrials.gov with LAPIX Therapeutics Inc. as lead sponsor.

NCT NCT05663853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05663853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Observational Study for Ex-vivo Evaluation of the Likelihood of Response to an Experimental Tolerance Restoration Therapy in Subjects Diagnosed With Multiple Sclerosis (MS)
Lead sponsor
LAPIX Therapeutics Inc.
Phase
Observational
Overall status
Completed
Start date
March 28, 2023
Completion date
April 30, 2024
Enrollment
137 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, primary progressive, multiple sclerosis, relapsing-remitting, multiple sclerosis, secondary progressive